表紙
市場調査レポート

慢性心不全:パイプライン製品の分析

Chronic Heart Failure - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264093
出版日 ページ情報 英文 157 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
慢性心不全:パイプライン製品の分析 Chronic Heart Failure - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 157 Pages
概要

慢性心不全は、心臓のポンプ機能が低下して、全身に十分な血液・栄養を送ることができなくなる厳しい状況を指します。症状は徐々に進行していきます。一般的に、咳、疲労感、虚弱、失神、食欲不振、夜間の尿意、息切れ、肝臓や腹部の腫れ(肥大)、足・足首のむくみ、体重増加などの症状が見られます。危険因子は、高血圧、冠動脈疾患、心臓発作、糖尿病、アルコール摂取などが挙げられます。

当レポートでは、慢性心不全に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性心不全の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Bayer AG
  • Capricor Therapeutics, Inc.
  • Celyad SA
  • Juventas Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • Les Laboratoires Servier SAS
  • Mast Therapeutics, Inc.
  • Mesoblast Limited
  • Novartis AG
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Sanofi
  • Stemedica Cell Technologies, Inc.
  • Vichem Chemie Research Ltd.
  • Zensun (Shanghai) Sci & Tech Co., Ltd.

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (sacubitril + valsartan)
  • BAY-1067197
  • beperminogene perplasmid
  • C3BSCQR-1
  • cenderitide
  • CLR-325
  • F-373280
  • finerenone
  • furosemide
  • ivabradine hydrochloride
  • JVS-100
  • MPC-150IM
  • Neucardin
  • omecamtiv mecarbil MR
  • PB-1046
  • rivaroxaban
  • SAR-296968
  • serelaxin
  • クエン酸シルデナフィル
  • 慢性心不全向け小分子
  • 循環器疾患・中枢神経障害・代謝障害・ 呼吸器疾患・感染性疾患・毒物学向け幹細胞療法
  • 循環器疾患向けエリスロポエチン受容体活性合成ペプチド
  • vepoloxamer
  • vericiguat

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7839IDB

Summary

Global Markets Direct's, 'Chronic Heart Failure - Pipeline Review, H1 2016', provides an overview of the Chronic Heart Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
  • The report reviews pipeline therapeutics for Chronic Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Heart Failure therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Heart Failure

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Heart Failure Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Heart Failure - Overview
    • Pipeline Products for Chronic Heart Failure - Comparative Analysis
  • Chronic Heart Failure - Therapeutics under Development by Companies
  • Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes
  • Chronic Heart Failure - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Heart Failure - Products under Development by Companies
  • Chronic Heart Failure - Products under Investigation by Universities/Institutes
  • Chronic Heart Failure - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • AnGes MG, Inc.
    • Bayer AG
    • Capricor Therapeutics, Inc.
    • Celyad SA
    • Juventas Therapeutics, Inc.
    • Laboratoires Pierre Fabre SA
    • Les Laboratoires Servier SAS
    • Mast Therapeutics, Inc.
    • Mesoblast Limited
    • Novartis AG
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • Sanofi
    • Stemedica Cell Technologies, Inc.
    • Vichem Chemie Research Ltd.
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Chronic Heart Failure - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (sacubitril + valsartan) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1067197 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C3BSCQR-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cenderitide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLR-325 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-373280 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • finerenone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • furosemide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ivabradine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-150IM - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neucardin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omecamtiv mecarbil MR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-1046 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-296968 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • serelaxin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Chronic Heart Failure - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vepoloxamer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vericiguat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chronic Heart Failure - Recent Pipeline Updates
  • Chronic Heart Failure - Dormant Projects
  • Chronic Heart Failure - Discontinued Products
  • Chronic Heart Failure - Product Development Milestones
    • Featured News & Press Releases
      • Apr 04, 2016: Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure
      • Apr 04, 2016: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo
      • Apr 02, 2016: New analyses show Novartis' Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless
      • Mar 22, 2016: CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center
      • Mar 18, 2016: Celyad notifies the European Medicines Agency of its intention to file a Marketing Authorization Application for C-Cure
      • Jan 20, 2016: Breakthrough drug for heart failure now available in the UK
      • Dec 23, 2015: Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference
      • Dec 21, 2015: Celyad receives clearance from the US FDA on its CHART-2 Phase III IND
      • Dec 02, 2015: New heart failure therapy projected to increase life expectancy
      • Dec 01, 2015: CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Heart Failure, H1 2016
  • Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Chronic Heart Failure - Pipeline by Amgen Inc., H1 2016
  • Chronic Heart Failure - Pipeline by AnGes MG, Inc., H1 2016
  • Chronic Heart Failure - Pipeline by Bayer AG, H1 2016
  • Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H1 2016
  • Chronic Heart Failure - Pipeline by Celyad SA, H1 2016
  • Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H1 2016
  • Chronic Heart Failure - Pipeline by Mesoblast Limited, H1 2016
  • Chronic Heart Failure - Pipeline by Novartis AG, H1 2016
  • Chronic Heart Failure - Pipeline by Pfizer Inc., H1 2016
  • Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016
  • Chronic Heart Failure - Pipeline by Sanofi, H1 2016
  • Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H1 2016
  • Chronic Heart Failure - Dormant Projects, H1 2016
  • Chronic Heart Failure - Dormant Projects (Contd..1), H1 2016
  • Chronic Heart Failure - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Chronic Heart Failure, H1 2016
  • Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top